ALT Ishares Diversified Alternatives Trust

Alteon Announces Investor Update Conference Call Thursday, September 9, 2004, 2:00 P.M. Eastern Time - Conference Call to be Webcast - PARSIPPANY, N.J., Sept. 1 /PRNewswire-FirstCall/ -- Alteon Inc. (AMEX:ALT) announced that it will hold a regularly scheduled investor update conference call on Thursday, September 9, 2004 at 2:00 p.m. ET. Anyone interested in participating in the live conference call should RSVP to Nancy Regan at . There will be a full question and answer period during the call. The call-in telephone number for the conference call will be 1-800-500-0177. International participants may call +719-457-2679. Participants should call approximately 5-10 minutes before 2:00 p.m. In addition, the conference call will be accessible through a webcast on the company website, http://www.alteon.com/ in the Investor Relations section, and a digital rebroadcast will be available through September 16, 2004 at 11:59 P.M. by dialing 1-888-203-1112, passcode 896642 for domestic callers and +719-457-0820, passcode 896642 for international callers. About Alteon Alteon is developing several new classes of drugs that reverse or slow down diseases of aging and complications of diabetes. These compounds have an impact on a fundamental pathological process caused by protein-glucose complexes called Advanced Glycation End-products (A.G.E.s). The formation and crosslinking of A.G.E.s lead to a loss of flexibility and function in body tissues, organs and vessels and have been shown to be a causative factor in many age-related diseases and diabetic complications. Alteon has created a library of novel classes of compounds targeting the A.G.E. Pathway. Alteon's lead compound alagebrium chloride (formerly ALT-711), the only A.G.E. Crosslink Breaker in advanced human testing, has demonstrated safety and efficacy in several Phase 2 trials and is actively being developed for systolic hypertension and heart failure. Ongoing clinical trials include SPECTRA (Systolic Pressure Efficacy and Safety Trial of Alagebrium) and PEDESTAL (Patients with Impaired Ejection Fraction and Diastolic Dysfunction: Efficacy and Safety Trial of ALagebrium). For more information on Alteon, visit the company's website at http://www.alteon.com/. Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, those relating to technology and product development (including the possibility that early clinical trial results may not be predictive of results that will be obtained in large-scale testing or that any clinical trials will not demonstrate sufficient safety and efficacy to obtain requisite approvals or will not result in marketable products), regulatory approval processes, intellectual property rights and litigation, competitive products, ability to obtain financing, and other risks identified in Alteon's filings with the Securities and Exchange Commission. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. Alteon undertakes no obligation to publicly release the result of any revision to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. DATASOURCE: Alteon Inc. CONTACT: Susan M. Pietropaolo, Director, Corporate Communications & Investor Relations of Alteon, +1-201-818-5537 Web site: http://www.alteon.com/

Copyright